An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Janssen Research & Development, LLC
ClinicalTrials.gov Identifier:
NCT00488631
First received: June 18, 2007
Last updated: July 21, 2014
Last verified: July 2014
  Purpose

The purpose of this study is to assess the safety and efficacy of golimumab administered subcutaneously (under the skin) injections in maintenance therapy.


Condition Intervention Phase
Colitis, Ulcerative
Biological: Placebo
Biological: Golimumab 50 mg
Biological: Golimumab 100 mg
Biological: Golimumab 200 mg
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis

Resource links provided by NLM:


Further study details as provided by Janssen Research & Development, LLC:

Primary Outcome Measures:
  • Number of Participants in Clinical Response Through Week 54 [ Time Frame: Induction Baseline, Week 0 through Week 54 ] [ Designated as safety issue: No ]
    Clinical response is defined as decrease from induction baseline in Mayo score by greater than or equal to (>=) 30 percent and >= 3, with either decrease from induction baseline in rectal bleeding subscore of >= 1 or rectal bleeding subscore of 0 or 1. Participants who lost clinical response prior to Week 54 were considered not to meet endpoint. Mayo score is sum of 4 subscores (ie, stool frequency, rectal bleeding, endoscopic findings, physician's global assessment); each rated on scale from 0 to 3, with higher scores indicating more severe disease. Total Mayo score value ranges from 0 to 12.


Secondary Outcome Measures:
  • Number of Participants With Clinical Remission at Both Week 30 and Week 54 [ Time Frame: Week 30 and Week 54 ] [ Designated as safety issue: No ]
    Clinical remission is defined as a Mayo score of less than or equal to 2, with no individual sub-score greater than 1. The Mayo score is sum of 4 sub-scores (i.e., stool frequency, rectal bleeding, endoscopic findings, and physician's global assessment); each rated on a scale from 0 to 3, with higher scores indicating more severe disease. The total Mayo score value ranges from 0 to 12. The number of participants in clinical remission at both the weeks that is Week 30 as well as Week 54 will be reported.

  • Number of Participants With Mucosal Healing at Both Week 30 and Week 54 [ Time Frame: Week 30 and Week 54 ] [ Designated as safety issue: No ]
    Mucosal healing is determined from the endoscopy sub-score of the Mayo score. Mucosal healing is defined as an endoscopy sub-score of 0 or 1. Higher score indicates higher severity of disease. Endoscopy sub-score ranges from 0 (normal or inactive disease) to 3 (severe disease; spontaneous bleeding and ulceration). The number of participants with mucosal healing at both the weeks that is Week 30 as well as Week 54 will be reported.

  • Number of Participants With Clinical Remission at Both Week 30 and 54 Among Participants With Clinical Remission at Week 0 of Maintenance Study [ Time Frame: Week 30 and Week 54 ] [ Designated as safety issue: No ]
    Clinical remission is defined as a Mayo score of less than or equal to 2, with no individual sub-score greater than 1. The Mayo score is sum of 4 sub-scores (i.e., stool frequency, rectal bleeding, endoscopic findings, and physician's global assessment); each rated on a scale from 0 to 3, with higher scores indicating more severe disease. The total Mayo score value ranges from 0 to 12. The number of participants in clinical remission at both the weeks that is Week 30 as well as Week 54 will be reported.

  • Number of Participants With Clinical Remission at Week 54 and Not Receiving Concomitant Corticosteroids Among Participants on Corticosteroids at Week 0 of Maintenance Study [ Time Frame: Week 54 ] [ Designated as safety issue: No ]
    Clinical remission is defined as a Mayo score of less than or equal to 2, with no individual sub-score greater than 1. The Mayo score is sum of 4 sub-scores (i.e., stool frequency, rectal bleeding, endoscopic findings, and physician's global assessment); each rated on a scale from 0 to 3, with higher scores indicating more severe disease. The total Mayo score value ranges from 0 to 12.


Enrollment: 1228
Study Start Date: September 2007
Estimated Study Completion Date: May 2015
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Golimumab induction responders (GLM-I-Rsp)-Placebo Maintenance
Participants in clinical response to golimumab at Week 6 of induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and randomized to placebo subcutaneous (under the skin) injection matching to golimumab administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631). Participants with loss of clinical response will have their dose increased to golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52.
Biological: Placebo
Participants receive placebo subcutaneous injection matching to golimumab administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631).
Biological: Golimumab 100 mg
Participants receive golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631) initially or after dose adjustment following loss of clinical response.
Experimental: GLM-I-Rsp-Golimumab 50 mg Maintenance
Participants in clinical response to golimumab at Week 6 of induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and randomized to golimumab 50 mg subcutaneous injection administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631). Participants with loss of clinical response will be re-randomized to receive golimumab 50 mg or 100 mg subcutaneous injections every 4 weeks through Week 52.
Biological: Golimumab 50 mg
Participants receive golimumab 50 mg subcutaneous injection administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631).
Biological: Golimumab 100 mg
Participants receive golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631) initially or after dose adjustment following loss of clinical response.
Experimental: GLM-I-Rsp-Golimumab 100 mg Maintenance
Participants in clinical response to golimumab at Week 6 of induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and randomized to golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631). Participants with loss of clinical response will be re-randomized to receive golimumab 100 mg or 200 mg subcutaneous injections every 4 weeks through Week 52.
Biological: Golimumab 100 mg
Participants receive golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631) initially or after dose adjustment following loss of clinical response.
Biological: Golimumab 200 mg
Participants receiving golimumab 100 mg initially who on loss of clinical response receive golimumab 200 mg administered every 4 weeks through Week 52.
Placebo Comparator: Placebo induction responders (PBO-I-Rsp)-Placebo Maintenance
Participants in clinical response to placebo at Week 6 of induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and received placebo subcutaneous injection matching to golimumab administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631); not randomized. Participants with loss of clinical response will have their dose increased to golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52.
Biological: Placebo
Participants receive placebo subcutaneous injection matching to golimumab administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631).
Biological: Golimumab 100 mg
Participants receive golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631) initially or after dose adjustment following loss of clinical response.
Experimental: PBO-I-nonRsp-Golimumab 100 mg Maintenance
Participants not in clinical response to placebo at Week 6 induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and received golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631); not randomized.
Biological: Golimumab 100 mg
Participants receive golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631) initially or after dose adjustment following loss of clinical response.
Experimental: GLM-I-nonRsp-Golimumab 100 mg Maintenance
Participants not in clinical response to golimumab at Week 6 of induction study and received golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631); not randomized.
Biological: Golimumab 100 mg
Participants receive golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631) initially or after dose adjustment following loss of clinical response.

Detailed Description:

This was a Phase 3, multicenter (conducted in more than one center), placebo-controlled (an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial), double-blind (neither the Physician nor the participant know about the study medication), parallel-group (a medical research study comparing the response in 2 or more groups of participants receiving different interventions), randomized-withdrawal study. Participants who were in clinical response to golimumab at Week 6 in induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) will be randomly assigned in a 1:1:1 ratio at Week 0 of this study to receive 1 of the following maintenance treatment regimens administered subcutaneously every 4 weeks through Week 52: placebo, golimumab 50 mg, or golimumab 100 mg. Participants who were in clinical response to placebo and participants who were not in clinical response to golimumab or placebo at Week 6 in induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) will not be randomly assigned but will be eligible to be enrolled in the study (i.e., the nonrandomized group) and received the following treatment regimens: placebo, golimumab 100 mg and golimumab 100 mg. Dose adjustment will be done for participants who were in clinical response to golimumab or placebo during induction studies C0524T16 (NCT00488774) or C0524T17 (NCT00487539) but lose clinical response during maintenance study C0524T18 (NCT00488631). On completing this study, participant will have the opportunity to continue to receive study medication in a study extension that will last up to approximately 3 years. Efficacy will be primarily evaluated by assessing the clinical response using Mayo Score. Participants' safety will be monitored throughout the study.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participants who received all study agent administrations and completed the Week 6 Mayo score evaluation in induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539)
  • Participants who completed the Week 0 visit for this maintenance study C0524T18 (NCT00488631) on the same day as the Week 6 visit of the induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539)

Exclusion Criteria:

  • Participants who increased the dose of their concomitant (given at the same time) UC medications since Week 0 of induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539)
  • Participants who initiated a concomitant UC medication since Week 0 of an induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539)
  • Participants who had a partial or total colectomy (surgery to remove part or all of the colon) or an ostomy (surgical construction of an artificial opening (stoma) for external fistulization of a duct or vessel by insertion of a tube with or without a supportive stent) since Week 0 of an induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539)
  • Participants with signs or symptoms of latent or active granulomatous infection (including TB); a nontuberculous mycobacterial infection or opportunistic infection; or infection with HIV (Human Immunodeficiency Virus), hepatitis B, or hepatitis C
  • Participants with signs and symptoms of any malignancy or suggestive of a possible lymphoproliferative disease (disorders characterized by proliferation of lymphoid tissue, general or unspecified)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00488631

  Hide Study Locations
Locations
United States, Alabama
Birmingham, Alabama, United States
United States, Arkansas
Little Rock, Arkansas, United States
United States, California
Anaheim, California, United States
Merced, California, United States
Orange, California, United States
Roseville, California, United States
San Diego, California, United States
United States, Colorado
Lakewood, Colorado, United States
Littleton, Colorado, United States
United States, Connecticut
Bristol, Connecticut, United States
United States, Delaware
Newark, Delaware, United States
United States, Florida
Boca Raton, Florida, United States
Gainesville, Florida, United States
Hialeah, Florida, United States
Hollywood, Florida, United States
Jacksonville, Florida, United States
N Miami Beach, Florida, United States
Naples, Florida, United States
New Port Richey, Florida, United States
Port Orange, Florida, United States
Tampa, Florida, United States
Winter Park, Florida, United States
Zephyrhills, Florida, United States
United States, Georgia
Atlanta, Georgia, United States
Decatur, Georgia, United States
Savannah, Georgia, United States
Snellville, Georgia, United States
United States, Illinois
Arlington Heights, Illinois, United States
Chicago, Illinois, United States
United States, Iowa
Clive, Iowa, United States
Fort Dodge, Iowa, United States
United States, Kansas
Pratt, Kansas, United States
Topeka, Kansas, United States
United States, Kentucky
Lexington, Kentucky, United States
Louisville, Kentucky, United States
United States, Louisiana
Monroe, Louisiana, United States
United States, Maryland
Hagerstown, Maryland, United States
Hollywood, Maryland, United States
Laurel, Maryland, United States
United States, Massachusetts
Worcester, Massachusetts, United States
United States, Michigan
Ann Arbor, Michigan, United States
Dearborn, Michigan, United States
Troy, Michigan, United States
United States, Minnesota
Plymouth, Minnesota, United States
Rochester, Minnesota, United States
United States, Mississippi
Pascagoula, Mississippi, United States
Tupelo, Mississippi, United States
United States, Missouri
Mexico, Missouri, United States
United States, Nevada
Las Vegas, Nevada, United States
United States, New Hampshire
Lebanon, New Hampshire, United States
United States, New Jersey
Egg Harbor Township, New Jersey, United States
United States, New York
Great Neck, New York, United States
Huntington, New York, United States
New York, New York, United States
Rochester, New York, United States
United States, North Carolina
Asheville, North Carolina, United States
Boone, North Carolina, United States
Charlotte, North Carolina, United States
Harrisburg, North Carolina, United States
Kinston, North Carolina, United States
Morganton, North Carolina, United States
New Bern, North Carolina, United States
Raleigh, North Carolina, United States
Wilmington, North Carolina, United States
Winston Salem, North Carolina, United States
United States, North Dakota
Fargo, North Dakota, United States
United States, Ohio
Cincinnati, Ohio, United States
Cleveland, Ohio, United States
Colombus, Ohio, United States
United States, Oklahoma
Norman, Oklahoma, United States
Oklahoma City, Oklahoma, United States
Tulsa, Oklahoma, United States
United States, Oregon
Portland, Oregon, United States
United States, Pennsylvania
Limerick, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
United States, South Carolina
Charleston, South Carolina, United States
Columbia, South Carolina, United States
United States, Tennessee
Germantown, Tennessee, United States
Nashville, Tennessee, United States
United States, Texas
Austin, Texas, United States
Dallas, Texas, United States
Galveston, Texas, United States
Houston, Texas, United States
United States, Utah
Logan, Utah, United States
Ogden, Utah, United States
United States, Vermont
Burlington, Vermont, United States
United States, Virginia
Chesapeake, Virginia, United States
Christiansburg, Virginia, United States
Fairfax, Virginia, United States
Richmond, Virginia, United States
United States, Washington
Bellevue, Washington, United States
Seattle, Washington, United States
Spokane, Washington, United States
Tacoma, Washington, United States
United States, Wisconsin
Madison, Wisconsin, United States
Milwaukee, Wisconsin, United States
Australia
Adelaide, Australia
Bankstown, Australia
Box Hill, Australia
Brisbane, Australia
Cairns, Australia
Fitzroy, Australia
Fremantle, Australia
Herston, Australia
Launceston, Australia
Malvern, Australia
Parkville, Australia
Prahran, Australia
Westmead, Australia
Austria
Innsbruck, Austria
Wien N/A, Austria
Belgium
Bonheiden, Belgium
Brussel, Belgium
Gent, Belgium
Leuven, Belgium
Liège, Belgium
Roeselare, Belgium
Bulgaria
Bulgaria, Bulgaria
Pleven, Bulgaria
Plovdiv, Bulgaria
Rousse, Bulgaria
Sofia, Bulgaria
Canada, Alberta
Calgary, Alberta, Canada
Canada, British Columbia
Vancouver, British Columbia, Canada
Victoria, British Columbia, Canada
Canada, Manitoba
Winnipeg, Manitoba, Canada
Canada, Ontario
Barrie, Ontario, Canada
Chatham, Ontario, Canada
Hamilton, Ontario, Canada
Kingston, Ontario, Canada
London, Ontario, Canada
Vaughan, Ontario, Canada
Canada, Quebec
Montreal, Quebec, Canada
Canada, Saskatchewan
Saskatoon, Saskatchewan, Canada
Canada
Quebec, Canada
Toronto, Canada
Windsor, Canada
Czech Republic
Hradec Kralove, Czech Republic
Litomerice, Czech Republic
Ostrava, Czech Republic
Èeské Budìjovice 1, Czech Republic
Denmark
Aalborg, Denmark
Aarhus C., Denmark
Hvidovre, Denmark
Odense C, Denmark
France
Amiens Cedex 1 80, France
Bordeaux 33, France
Clichy, France
Lille Cedex, France
Marseille Cedex 13, France
Nice Cedex 3, France
Paris, France
Rouen, France
Germany
Aachen, Germany
Berlin, Germany
Berlin Be, Germany
Bochum, Germany
Frankfurt, Germany
Hamburg, Germany
Hannover, Germany
Heidelberg, Germany
Herne, Germany
Jena, Germany
Kiel, Germany
Magdeburg, Germany
Minden, Germany
Muenchen, Germany
München, Germany
Münster, Germany
Neustadt, Germany
Stade, Germany
Hungary
Balatonfured, Hungary
Budapest, Hungary
Budapest N/A, Hungary
Debrecen, Hungary
Dunaujvaros, Hungary
Gyula, Hungary
Gyulai Ut 18, Hungary
Gyõr, Hungary
Miskolc, Hungary
Mosonmagyarovar, Hungary
Pécs, Hungary
Siofok, Hungary
Sopron, Hungary
Szeged, Hungary
Szekesfehervar, Hungary
Szekszard, Hungary
Szombathely, Hungary
Veszprém, Hungary
Zalaegerszeg, Hungary
India
Bangalore, India
Chennai, India
Hyderabad, India
Hyderabad Andh Prad, India
Jaipur, India
Karnad, India
Lucknow Gpo, India
Ludhiana, India
New Delhi, India
Pune, India
Vishakapatanam, India
Israel
Afula, Israel
Beer Sheva, Israel
Beer Yaakov, Israel
Haifa, Israel
Hedera, Israel
Jerusalem, Israel
Kfar Sava, Israel
Kiryat Bialik, Israel
Nazareth, Israel
Petah-Tikv, Israel
Rechovot, Israel
Tel Hashomer, Israel
Tel-Aviv, Israel
Japan
Bunkyo, Japan
Bunkyo-Ku, Japan
Chikushinoshi, Japan
Fukuoka, Japan
Hiroshima, Japan
Kagoshima, Japan
Kurashiki, Japan
Kurume, Japan
Nagoya, Japan
Nishinomiya, Japan
Okayama, Japan
Osaka, Japan
Sakura, Japan
Sapporo, Japan
Sapporo-Shi, Japan
Tokyo, Japan
Tokyo N/A, Japan
Yokkaichi, Japan
Latvia
Balvi, Latvia
Daugavpils, Latvia
Riga, Latvia
Lithuania
Kaunas, Lithuania
Klaipeda, Lithuania
Siauliai, Lithuania
Vilnius, Lithuania
Vilnius Lt, Lithuania
Netherlands
Amsterdam, Netherlands
Ede Gld, Netherlands
Groningen, Netherlands
Leiden, Netherlands
Nieuwegein, Netherlands
Rotterdam, Netherlands
New Zealand
Auckland, New Zealand
Christchurch, New Zealand
Dunedin, New Zealand
Hamilton, New Zealand
Hastings, New Zealand
Poland
Bialystok N/A, Poland
Bydgoszcz N/A, Poland
Czestochowa, Poland
Elblag, Poland
Gdansk, Poland
Gdansk N/A, Poland
Krakow, Poland
Krakow N/A, Poland
Kraków N/A, Poland
Lodz, Poland
Lublin, Poland
Opole N/A, Poland
Skierniewice, Poland
Sopot, Poland
Szczecin, Poland
Torun, Poland
Warszawa, Poland
Warszawa N/A, Poland
Romania
Bucuresti, Romania
Cluj-Napoca, Romania
Iasi, Romania
Targu Mures, Romania
Timisoara, Romania
Russian Federation
Moscow, Russian Federation
Novosibirsk, Russian Federation
Omsk, Russian Federation
Saint Petersburg, Russian Federation
Smolensk, Russian Federation
St Petersburg, Russian Federation
St-Petersburg, Russian Federation
Yaroslavl, Russian Federation
Serbia
Belgrade, Serbia
Beograd, Serbia
Nis, Serbia
Zemun, Serbia
Slovakia
Bratislava, Slovakia
Martin, Slovakia
Nitra, Slovakia
Nove Mesto Nad Vahom, Slovakia
Presov, Slovakia
Trnava, Slovakia
South Africa
Cape Town, South Africa
Cape Town West Cape, South Africa
Durban N/A, South Africa
Plumstead West Cape, South Africa
Pretoria Gauteng, South Africa
Sweden
Göteborg, Sweden
Stockholm, Sweden
Ukraine
Donetsk, Ukraine
Ivano, Ukraine
Kharkiv, Ukraine
Kiev, Ukraine
Kyiv, Ukraine
Lviv, Ukraine
Poltava, Ukraine
Simferopol, Ukraine
Vinnitsa, Ukraine
Zhaporozhia 69104, Ukraine
Sponsors and Collaborators
Janssen Research & Development, LLC
Merck Sharp & Dohme Corp.
Investigators
Study Director: Janssen Research & Development, LLC Clinical Trial Janssen Research & Development, LLC
  More Information

No publications provided by Janssen Research & Development, LLC

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Janssen Research & Development, LLC
ClinicalTrials.gov Identifier: NCT00488631     History of Changes
Other Study ID Numbers: CR014179, 2006-003399-37, C0524T18
Study First Received: June 18, 2007
Results First Received: May 1, 2013
Last Updated: July 21, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Janssen Research & Development, LLC:
Colitis, Ulcerative
Golimumab
CNTO 148

Additional relevant MeSH terms:
Colitis
Colitis, Ulcerative
Ulcer
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Colonic Diseases
Intestinal Diseases
Inflammatory Bowel Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on July 26, 2014